Medgend Icon

Ledgend of Medicine







discontinued


Kyprolis FDA Approved Drugs

KYPROLIS [CarfilzomibC40H57N5O7]
RX
-
30mg/vial (intravenous powder)
60mg/vial (intravenous powder)
Onyx TherapJun 3, 2016
  • Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.